Ior Partners

Ophthalmic surgery

Based in MO

Share:𝕏LinkedInFacebook
🤖

AI Overview

With $300K in lobbying spend across 11 quarterly filings, Ior Partners is an active lobbying client. Their lobbying covers 1 issue area. Active from 2020 to 2023.

$300K
Total Spend
3
Years Active
1
Firms Hired
8
Lobbyists Deployed
1
Issues Lobbied

Spending Trend

View as table
YearLobbying Spend
2020$0
2022$120K
2023$180K

Issues Lobbied

Medicare/Medicaid

Lobbying Firms

Jeffrey J. Kimbell & Associates, INC.

Lobbyists

Kenneth HodgeJeffrey KimbellJodie LockhartJohn RayDavid RudloffKeith StuddardJohn HerzogKelsey Carlson

What They Lobby About

These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Medicare/Medicaid

  • •Issues related to reimbursement for ophthalmology procedures
  • •Issues related to ophthalmic surgery.
  • •Issues related to Medicare reimbursement for ophthalmology procedures
  • •Issues related to reimbursement for eye care procedures

Related Analysis

📈 Client Trajectories
See how this client compares to others over time
🎯 Market Concentration
How concentrated is the lobbying market?
🚀 Spending Momentum
Which issues are surging right now?

Related Investigations

Federal Lobbying Statistics 2025
The definitive stats — $37.7B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.

Similar Clients

St Shared Services LLC DBA Keenova Therapeutics (FKA St Shared Services LLC DBA
$8.4M total spend
Air Evac Lifeteam
$7.2M total spend
American Association of Bioanalysts
$2.6M total spend
Mallinckrodt Pharmaceuticals
$1.5M total spend
Ascension Health Alliance D/B/A Ascension
$1.5M total spend

Explore More

← All Clients⚖️ Compare Clients💵 ROI Calculator🔍 Investigations📖 How Lobbying Works🕸️ Network Analysis🏛️ Agency Pressure

Data Sources: Senate LDA Filings

Last updated: February 2026

This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.